Proactive Investors - Run By Investors For Investors

Auscann Group makes steady progress towards production of cannabinoid medicines

Auscann has a vertically integrated strategy beginning with cultivation and production, through to manufacture and distribution of products.
cannabis medicines
Partners include industry leaders such as Canopy Growth Corp and Fundacion Daya

Auscann Group Holdings Ltd (ASX:AC8) is continuing to make steady progress towards releasing its first medicinal cannabis products during the financial year 2019.

The company has established several strategic partnerships in Australia, Chile and Canada and is advancing its position as a fully-integrated cannabinoid pharmaceutical company.

READ: AusCann Group well positioned as investors move in on medical cannabis sector

During the year ended June 30, 2018, the company achieved important milestones across its operations, including new agreements, R&D breakthroughs and regulatory advances.

Post FY2018, Auscann raised over $35 million and remains well-funded to continue executing its strategic goals.

READ: Auscann Group raises more capital, well-funded for manufacturing cannabinoid medicines in Australia

AusCann managing director Elaine Darby said: “Progress has been made across all aspects of the company’s operations during this financial year.

“We are now several steps closer to our goal of providing patients with access to high-quality, economical and clinically-validated cannabinoid medicines.

“I’d like to personally thank all shareholders for their continued support and we look forward to delivering on our commitment to releasing our first medicinal cannabis products in 2019.”

READ: AusCann Group pilot study reveals unique capsule for cannabinoid medicines

AusCann aims to produce high quality, economical and clinically validated cannabinoid medicines.

It has a vertically integrated strategy beginning with cultivation and production, through to manufacture and distribution of products.

This is made possible through a number of partnerships with industry leaders such as Canopy Growth Corp and Fundacion Daya.

The company is initially targeting medications for neuropathic and chronic pain in Australia and internationally, a market estimated to be worth $9 billion in Australia alone.

Upcoming ASX Small and Mid-Cap Conference

AusCann will be presenting at the inaugural ASX Small and Mid-Cap Conference being held in Sydney on Thursday, September 6.

To attend the conference, please register here.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

cannabis leaf
May 09 2019
The company plans to leverage its portfolio of brands as well as its distribution network of more than 39,000 European pharmacies to maximize margins and profitability
medicinal cannabis concept
January 31 2019
Zelda has released its December quarterly report confirming multiple trials are on track.
windmill
May 08 2019
TGOD has been busy building out its facilities in Ontario, Quebec, and Jamaica and expects to reach combined production of 219,000 kilograms of cannabis around 2021

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use